Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents
The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.
1. An acid labile lipophilic molecular conjugate (ALLMC) of the formula 1:
wherein:
R is a 2′ hydroxyl residue of a paclitaxel, a docetaxel or an abeo-taxane compound;
R 1 is hydrogen;
R 2 is a C 5 -C 22 alkyl;
Y is selected from O, NR′ or S wherein R′ is hydrogen or C 1 -C 6 alkyl;
Z is O or S;
Q is O; and T is O;
or an enantiomer, diastereoisomer or mixtures thereof; and
a pharmaceutically acceptable salt thereof.
2. The acid labile lipophilic molecular conjugate of claim 1 , where the conjugate is of the formula:
3. The acid labile lipophilic molecular conjugate of claim 1 , where the conjugate is of the formula:
4. The acid labile lipophilic molecular conjugate of claim 1 , where the conjugate is of the formula:
5. The acid labile lipophilic molecular conjugate of claim 1 , where the conjugate is of the formula:
6. The acid labile lipophilic molecular conjugate of claim 1 , where the conjugate is of the formula:
7. The acid labile lipophilic molecular conjugate of claim 1 , where the conjugate is of the formula:
8. The acid labile lipophilic molecular conjugate of claim 1 , where the conjugate is of the formula:
9. The acid labile lipophilic molecular conjugate of claim 1 , where the abeo-taxane conjugate is of the formula:
10. The acid labile lipophilic molecular conjugate of claim 1 , where the abeo-taxane conjugate is of the formula:
11. The acid labile lipophilic molecular conjugate of claim 1 , where the abeo-taxane conjugate is of the formula:
12. A pharmaceutical composition comprising: a) a therapeutically effective amount of a compound of claim 1 , in the form of a single diastereoisomer; and b) a pharmaceutically acceptable excipient.
13. A method for the treatment of cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound or composition of claim 1 , to a patient in need of such treatment.
14. The method of claim 13 , wherein the cancer is selected from the group consisting of leukemia, neuroblastoma, glioblastoma, cervical, colorectal, pancreatic, renal and melanoma.
15. The method of claim 13 , wherein the cancer is selected from the group consisting of lung, breast, prostate, ovarian and head and neck.